<DOC>
	<DOCNO>NCT00739193</DOCNO>
	<brief_summary>The primary objective trial compare relative hemodynamic effect novel intravenous formulation amiodarone ( PM101 ) , administer immediate IV bolus push , placebo currentlyl available formulation Amiodarone IV , administer 10-minute IV infusion , systolic arterial pressure .</brief_summary>
	<brief_title>A Randomized , Placebo-Controlled , Double-Blind , Double Dummy Trial To Determine The Relative Effect Of Pm101 Versus Placebo And Amiodarone IV On Blood Pressure In Subjects With Stable Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Men woman &gt; 18 year age Screening , diagnosis stable congestive heart failure NYHA Functional Classification Heart Failure Class II , III , IV Documented leave ventricular ejection fraction â‰¤35 % within 6 month Screening , provide assessment within 4 week myocardial infarction Outpatient inpatient On stable dos medication treat congestive heart failure ( eg , betablockers , angiotensinconverting enzyme inhibitor/angiotensinreceptor antagonist , diuretic ) least 7 day dose trial drug Have 12lead electrocardiogram ( ECG ) Screening show clinically significant abnormality rate , rhythm , conduction ( highgrade atrioventricular block , bifascicular trifascicular block ) , would jeopardize safety ability accurately measure arterial pressure subject , opinion investigator Able communicate effectively trial personnel Able undergo study related procedure require protocol Adequately informed nature risk trial give write informed consent prior undergoing trialrelated procedure Women childbearing potential must negative pregnancy test Screening checkin trial site receive trial drug Day 1 must use effective medically acceptable form birth control duration trial ( Day 8 followup evaluation ) Known hypersensitivity allergy amiodarone , Captisol , Amiodarone IV , excipients Known hypersensitivity allergy iodine radioopaque dye Presence asthma pulmonary disease , thyroid disease ( hypo hyperthyroidism ) , hepatitis , liver disease would place subject increase risk treatment amiodarone , opinion investigator Myocardial infarction within 30 day Screening Functioning pacemaker Screening Day 1 Amiodarone administration within 7 day dose trial drug Cardiogenic shock , mark sinus bradycardia , second thirddegree atrioventricular block Any disease condition might compromise trial evaluation place subject increase risk treatment amiodarone , opinion investigator Any clinically significantly abnormal laboratory test Screening Day 1 would place subject increase risk treatment amiodarone , opinion investigator Women pregnant breastfeed Any subject receive investigational drug within 30 day dose trial drug Inability obtain 3 baseline SAP read 5 mm Hg difference among reading</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Blood Pressure</keyword>
</DOC>